TRAMPOLINE PHARMA, INC.

TrAMPoline Pharma is a cellular immunotherapy company developing personalized (autologous) therapies for solid tumor cancers. The company's lead therapeutic candidate, MightyTIL™, is a gene-engineered tumor infiltrating lymphocyte (TIL) therapy targeting orphan cancer indications including sarcoma, head and neck cancer, and melanoma. MightyTIL leverages TrAMPoline's patented coR8:Amp™ technology, which enhances TCR binding to cancer cells and increases T cell activation. The platform addresses a major gap in oncology: approximately 60% of cancer patients experience T cell immunotherapy failures. Co-founded by Dr. Eduardo Davila (CSO, University of Colorado) and Dr. Richard Duke (President, former GlobeImmune CEO), the company is based at the University of Colorado Anschutz Medical Campus in Aurora.